[
    {
        "AAON": {
            "defaultKeyStatistics": {
                "maxAge": 1,
                "priceHint": 2,
                "enterpriseValue": 9113043968,
                "forwardPE": 40.59058,
                "profitMargins": 0.15605,
                "floatShares": 66698125,
                "sharesOutstanding": 81013200,
                "sharesShort": 2958141,
                "sharesShortPriorMonth": 3547960,
                "sharesShortPreviousMonthDate": "2024-08-29 20:00:00",
                "dateShortInterest": "2024-09-29 20:00:00",
                "sharesPercentSharesOut": 0.0365,
                "heldPercentInsiders": 0.17525,
                "heldPercentInstitutions": 0.74164003,
                "shortRatio": 7.59,
                "shortPercentOfFloat": 0.051,
                "beta": 0.799,
                "category": null,
                "bookValue": 9.148,
                "priceToBook": 12.246393,
                "fundFamily": null,
                "legalType": null,
                "lastFiscalYearEnd": "2023-12-30 19:00:00",
                "nextFiscalYearEnd": "2024-12-30 19:00:00",
                "mostRecentQuarter": "2021-12-30 19:00:00",
                "earningsQuarterlyGrowth": -0.673,
                "netIncomeToCommon": 186371008,
                "trailingEps": 2.23,
                "forwardEps": 2.76,
                "pegRatio": 3.99,
                "lastSplitFactor": "3:2",
                "lastSplitDate": "2014-07-16 20:00:00",
                "enterpriseToRevenue": 7.631,
                "enterpriseToEbitda": 29.884
            },
            "summaryProfile": {
                "address1": "2425 South Yukon Avenue",
                "city": "Tulsa",
                "state": "OK",
                "zip": "74107",
                "country": "United States",
                "phone": "918 583 2266",
                "fax": "918 583 6094",
                "website": "https://www.aaon.com",
                "industry": "Building Products & Equipment",
                "sector": "Industrials",
                "longBusinessSummary": "AAON, Inc., together with its subsidiaries, engages in engineering, manufacturing, marketing, and selling air conditioning and heating equipment in the United States and Canada. The company operates through three segments: AAON Oklahoma, AAON Coil Products, and BASX. It offers rooftop units, data center cooling solutions, cleanroom systems, chillers, packaged outdoor mechanical rooms, air handling units, makeup air units, energy recovery units, condensing units, geothermal/water-source heat pumps, coils, and controls. The company markets and sells its products to retail, manufacturing, educational, lodging, supermarket, data centers, medical and pharmaceutical, and other commercial industries. It sells its products through a network of independent manufacturer representative organizations and internal sales force, as well as online. The company was incorporated in 1987 and is based in Tulsa, Oklahoma.",
                "fullTimeEmployees": 3856,
                "companyOfficers": [],
                "maxAge": 86400
            },
            "price": {
                "maxAge": 1,
                "preMarketChangePercent": -0.000266774,
                "preMarketChange": -0.0299988,
                "preMarketTime": "2024-10-14 08:46:18",
                "preMarketPrice": 112.42,
                "preMarketSource": "FREE_REALTIME",
                "postMarketChangePercent": 0.0,
                "postMarketChange": 0.0,
                "postMarketTime": "2024-10-14 16:08:27",
                "postMarketPrice": 112.03,
                "postMarketSource": "FREE_REALTIME",
                "regularMarketChangePercent": -0.0037349772,
                "regularMarketChange": -0.41999817,
                "regularMarketTime": "2024-10-14 16:00:01",
                "priceHint": 2,
                "regularMarketPrice": 112.03,
                "regularMarketDayHigh": 113.86,
                "regularMarketDayLow": 111.78,
                "regularMarketVolume": 259361,
                "averageDailyVolume10Day": 275770,
                "averageDailyVolume3Month": 406164,
                "regularMarketPreviousClose": 112.45,
                "regularMarketSource": "FREE_REALTIME",
                "regularMarketOpen": 112.86,
                "exchange": "NMS",
                "exchangeName": "NasdaqGS",
                "exchangeDataDelayedBy": 0,
                "marketState": "POSTPOST",
                "quoteType": "EQUITY",
                "symbol": "AAON",
                "underlyingSymbol": null,
                "shortName": "AAON, Inc.",
                "longName": "AAON, Inc.",
                "currency": "USD",
                "quoteSourceName": "Nasdaq Real Time Price",
                "currencySymbol": "$",
                "fromCurrency": null,
                "lastMarket": null,
                "marketCap": 9114805248
            },
            "financialData": {
                "maxAge": 86400,
                "currentPrice": 112.03,
                "targetHighPrice": 105.0,
                "targetLowPrice": 90.0,
                "targetMeanPrice": 99.75,
                "targetMedianPrice": 102.0,
                "recommendationMean": 2.3,
                "recommendationKey": "buy",
                "numberOfAnalystOpinions": 4,
                "totalCash": 2859000,
                "totalCashPerShare": 0.035,
                "ebitda": 304944000,
                "totalDebt": 40000000,
                "quickRatio": 1.573,
                "currentRatio": 2.994,
                "totalRevenue": 1194273024,
                "debtToEquity": 8.581,
                "revenuePerShare": 14.709,
                "returnOnAssets": 0.16217,
                "returnOnEquity": 0.26613,
                "freeCashflow": 84835624,
                "operatingCashflow": 226867008,
                "earningsGrowth": -0.686,
                "revenueGrowth": 0.168,
                "grossMargins": 0.36271998,
                "ebitdaMargins": 0.25534,
                "operatingMargins": 0.0399,
                "profitMargins": 0.15605,
                "financialCurrency": "USD"
            }
        }
    },
    {
        "ABSI": {
            "defaultKeyStatistics": {
                "maxAge": 1,
                "priceHint": 4,
                "enterpriseValue": 333666976,
                "forwardPE": -5.7746477,
                "profitMargins": 0.0,
                "floatShares": 85092303,
                "sharesOutstanding": 113556000,
                "sharesShort": 13343673,
                "sharesShortPriorMonth": 12082837,
                "sharesShortPreviousMonthDate": "2024-08-29 20:00:00",
                "dateShortInterest": "2024-09-29 20:00:00",
                "sharesPercentSharesOut": 0.1175,
                "heldPercentInsiders": 0.20318002,
                "heldPercentInstitutions": 0.61009,
                "shortRatio": 14.49,
                "shortPercentOfFloat": 0.1741,
                "beta": 2.196,
                "category": null,
                "bookValue": 1.952,
                "priceToBook": 2.1004097,
                "fundFamily": null,
                "legalType": null,
                "lastFiscalYearEnd": "2023-12-30 19:00:00",
                "nextFiscalYearEnd": "2024-12-30 19:00:00",
                "mostRecentQuarter": "2024-06-29 20:00:00",
                "netIncomeToCommon": -92264000,
                "trailingEps": -0.93,
                "forwardEps": -0.71,
                "pegRatio": -0.19,
                "lastSplitFactor": null,
                "enterpriseToRevenue": 102.667,
                "enterpriseToEbitda": -3.974
            },
            "summaryProfile": {
                "address1": "18105 SE Mill Plain Boulevard",
                "city": "Vancouver",
                "state": "WA",
                "zip": "98683",
                "country": "United States",
                "phone": "360 949 1041",
                "website": "https://www.absci.com",
                "industry": "Biotechnology",
                "sector": "Healthcare",
                "longBusinessSummary": "Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; and with AstraZeneca PLC for AI-driven drug discovery against an oncology target. The company was founded in 2011 and is headquartered in Vancouver, Washington.",
                "fullTimeEmployees": 155,
                "companyOfficers": [],
                "maxAge": 86400
            },
            "price": {
                "maxAge": 1,
                "preMarketChangePercent": 0.00702696,
                "preMarketChange": 0.0285997,
                "preMarketTime": "2024-10-14 09:25:06",
                "preMarketPrice": 4.0986,
                "preMarketSource": "FREE_REALTIME",
                "postMarketChangePercent": 0.0121952,
                "postMarketChange": 0.0500002,
                "postMarketTime": "2024-10-14 18:56:34",
                "postMarketPrice": 4.15,
                "postMarketSource": "FREE_REALTIME",
                "regularMarketChangePercent": 0.007370942,
                "regularMarketChange": 0.029999733,
                "regularMarketTime": "2024-10-14 16:00:01",
                "priceHint": 4,
                "regularMarketPrice": 4.1,
                "regularMarketDayHigh": 4.135,
                "regularMarketDayLow": 3.96,
                "regularMarketVolume": 566432,
                "averageDailyVolume10Day": 738990,
                "averageDailyVolume3Month": 975667,
                "regularMarketPreviousClose": 4.07,
                "regularMarketSource": "FREE_REALTIME",
                "regularMarketOpen": 4.04,
                "exchange": "NMS",
                "exchangeName": "NasdaqGS",
                "exchangeDataDelayedBy": 0,
                "marketState": "POSTPOST",
                "quoteType": "EQUITY",
                "symbol": "ABSI",
                "underlyingSymbol": null,
                "shortName": "Absci Corporation",
                "longName": "Absci Corporation",
                "currency": "USD",
                "quoteSourceName": "Nasdaq Real Time Price",
                "currencySymbol": "$",
                "fromCurrency": null,
                "lastMarket": null,
                "marketCap": 465579584
            },
            "financialData": {
                "maxAge": 86400,
                "currentPrice": 4.1,
                "targetHighPrice": 13.0,
                "targetLowPrice": 6.0,
                "targetMeanPrice": 8.29,
                "targetMedianPrice": 7.0,
                "recommendationMean": 2.0,
                "recommendationKey": "buy",
                "numberOfAnalystOpinions": 7,
                "totalCash": 145246000,
                "totalCashPerShare": 1.279,
                "ebitda": -83964000,
                "totalDebt": 13332000,
                "quickRatio": 5.705,
                "currentRatio": 6.486,
                "totalRevenue": 3250000,
                "debtToEquity": 6.019,
                "revenuePerShare": 0.033,
                "returnOnAssets": -0.23976,
                "returnOnEquity": -0.42237,
                "freeCashflow": -28843000,
                "operatingCashflow": -59989000,
                "revenueGrowth": -0.623,
                "grossMargins": 0.0,
                "ebitdaMargins": 0.0,
                "operatingMargins": -21.040161,
                "profitMargins": 0.0,
                "financialCurrency": "USD"
            }
        }
    },
    {
        "AAL": {
            "defaultKeyStatistics": {
                "maxAge": 1,
                "priceHint": 2,
                "enterpriseValue": 38255075328,
                "forwardPE": 6.0253806,
                "profitMargins": -0.00226,
                "floatShares": 645119656,
                "sharesOutstanding": 656704000,
                "sharesShort": 84430817,
                "sharesShortPriorMonth": 97032916,
                "sharesShortPreviousMonthDate": "2024-08-29 20:00:00",
                "dateShortInterest": "2024-09-29 20:00:00",
                "sharesPercentSharesOut": 0.1286,
                "heldPercentInsiders": 0.01274,
                "heldPercentInstitutions": 0.62601,
                "shortRatio": 2.1,
                "shortPercentOfFloat": 0.1459,
                "beta": 1.436,
                "impliedSharesOutstanding": 656704000,
                "category": null,
                "bookValue": -7.228,
                "fundFamily": null,
                "legalType": null,
                "lastFiscalYearEnd": "2023-12-30 19:00:00",
                "nextFiscalYearEnd": "2024-12-30 19:00:00",
                "mostRecentQuarter": "2024-06-29 20:00:00",
                "earningsQuarterlyGrowth": -0.464,
                "netIncomeToCommon": -121000000,
                "trailingEps": -0.18,
                "forwardEps": 1.97,
                "pegRatio": -11.73,
                "lastSplitFactor": null,
                "enterpriseToRevenue": 0.716,
                "enterpriseToEbitda": 7.428,
                "52WeekChange": -0.0058626533,
                "SandP52WeekChange": 0.33994555,
                "lastDividendValue": 0.1,
                "lastDividendDate": 1580774400
            },
            "summaryProfile": {
                "address1": "1 Skyview Drive",
                "city": "Fort Worth",
                "state": "TX",
                "zip": "76155",
                "country": "United States",
                "phone": "682 278 9000",
                "website": "https://www.aa.com",
                "industry": "Airlines",
                "industryKey": "airlines",
                "industryDisp": "Airlines",
                "sector": "Industrials",
                "sectorKey": "industrials",
                "sectorDisp": "Industrials",
                "longBusinessSummary": "American Airlines Group Inc., through its subsidiaries, operates as a network air carrier. The company provides scheduled air transportation services for passengers and cargo through its hubs in Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C., as well as through partner gateways in London, Doha, Madrid, Seattle/Tacoma, Sydney, and Tokyo. It operates a mainline fleet of 965 aircraft. The company was formerly known as AMR Corporation and changed its name to American Airlines Group Inc. in December 2013. American Airlines Group Inc. was founded in 1926 and is headquartered in Fort Worth, Texas.",
                "fullTimeEmployees": 137400,
                "companyOfficers": [],
                "maxAge": 86400
            },
            "price": {
                "maxAge": 1,
                "preMarketChangePercent": 0.0042409,
                "preMarketChange": 0.0500002,
                "preMarketTime": "2024-10-14 09:29:37",
                "preMarketPrice": 11.84,
                "preMarketSource": "FREE_REALTIME",
                "postMarketChangePercent": 0.00589719,
                "postMarketChange": 0.0699997,
                "postMarketTime": "2024-10-14 19:59:32",
                "postMarketPrice": 11.94,
                "postMarketSource": "FREE_REALTIME",
                "regularMarketChangePercent": 0.006785405,
                "regularMarketChange": 0.07999992,
                "regularMarketTime": "2024-10-14 16:00:01",
                "priceHint": 2,
                "regularMarketPrice": 11.87,
                "regularMarketDayHigh": 11.9476,
                "regularMarketDayLow": 11.7,
                "regularMarketVolume": 20281161,
                "averageDailyVolume10Day": 32958140,
                "averageDailyVolume3Month": 36472706,
                "regularMarketPreviousClose": 11.79,
                "regularMarketSource": "FREE_REALTIME",
                "regularMarketOpen": 11.84,
                "exchange": "NMS",
                "exchangeName": "NasdaqGS",
                "exchangeDataDelayedBy": 0,
                "marketState": "POSTPOST",
                "quoteType": "EQUITY",
                "symbol": "AAL",
                "underlyingSymbol": null,
                "shortName": "American Airlines Group, Inc.",
                "longName": "American Airlines Group Inc.",
                "currency": "USD",
                "quoteSourceName": "Nasdaq Real Time Price",
                "currencySymbol": "$",
                "fromCurrency": null,
                "toCurrency": null,
                "lastMarket": null,
                "marketCap": 7795076608
            },
            "financialData": {
                "maxAge": 86400,
                "currentPrice": 11.87,
                "targetHighPrice": 18.0,
                "targetLowPrice": 9.0,
                "targetMeanPrice": 11.86,
                "targetMedianPrice": 12.0,
                "recommendationMean": 2.7,
                "recommendationKey": "hold",
                "numberOfAnalystOpinions": 15,
                "totalCash": 8986999808,
                "totalCashPerShare": 13.685,
                "ebitda": 5150000128,
                "totalDebt": 39446999040,
                "quickRatio": 0.449,
                "currentRatio": 0.601,
                "totalRevenue": 53447999488,
                "revenuePerShare": 81.548,
                "returnOnAssets": 0.02779,
                "freeCashflow": 675000000,
                "operatingCashflow": 2015000064,
                "earningsGrowth": -0.463,
                "revenueGrowth": 0.02,
                "grossMargins": 0.23937,
                "ebitdaMargins": 0.09636,
                "operatingMargins": 0.09823,
                "profitMargins": -0.00226,
                "financialCurrency": "USD"
            }
        }
    },
    {
        "ABUS": {
            "defaultKeyStatistics": {
                "maxAge": 1,
                "priceHint": 4,
                "enterpriseValue": 594168640,
                "forwardPE": -11.028571,
                "profitMargins": 0.0,
                "floatShares": 135509628,
                "sharesOutstanding": 188782000,
                "sharesShort": 7358461,
                "sharesShortPriorMonth": 6064382,
                "sharesShortPreviousMonthDate": "2024-08-29 20:00:00",
                "dateShortInterest": "2024-09-29 20:00:00",
                "sharesPercentSharesOut": 0.039,
                "heldPercentInsiders": 0.22304001,
                "heldPercentInstitutions": 0.51618,
                "shortRatio": 4.24,
                "shortPercentOfFloat": 0.0495,
                "beta": 1.907,
                "impliedSharesOutstanding": 189270000,
                "category": null,
                "bookValue": 0.649,
                "priceToBook": 5.947612,
                "fundFamily": null,
                "legalType": null,
                "lastFiscalYearEnd": "2023-12-30 19:00:00",
                "nextFiscalYearEnd": "2024-12-30 19:00:00",
                "mostRecentQuarter": "2024-06-29 20:00:00",
                "netIncomeToCommon": -77087000,
                "trailingEps": -0.45,
                "forwardEps": -0.35,
                "lastSplitFactor": "1:5",
                "lastSplitDate": "2010-11-03 20:00:00",
                "enterpriseToRevenue": 59.057,
                "enterpriseToEbitda": -7.336,
                "52WeekChange": 1.0423281,
                "SandP52WeekChange": 0.33994555
            },
            "summaryProfile": {
                "address1": "701 Veterans Circle",
                "city": "Warminster",
                "state": "PA",
                "zip": "18974",
                "country": "United States",
                "phone": "267 469 0914",
                "website": "https://www.arbutusbio.com",
                "industry": "Biotechnology",
                "industryKey": "biotechnology",
                "industryDisp": "Biotechnology",
                "sector": "Healthcare",
                "sectorKey": "healthcare",
                "sectorDisp": "Healthcare",
                "longBusinessSummary": "Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.",
                "fullTimeEmployees": 73,
                "companyOfficers": [],
                "maxAge": 86400
            },
            "price": {
                "maxAge": 1,
                "preMarketChangePercent": 0.0,
                "preMarketChange": 0.0,
                "preMarketTime": "2024-10-14 09:29:59",
                "preMarketPrice": 3.88,
                "preMarketSource": "FREE_REALTIME",
                "postMarketChangePercent": 0.0233161,
                "postMarketChange": 0.0900002,
                "postMarketTime": "2024-10-14 19:45:37",
                "postMarketPrice": 3.95,
                "postMarketSource": "FREE_REALTIME",
                "regularMarketChangePercent": -0.0051546954,
                "regularMarketChange": -0.02000022,
                "regularMarketTime": "2024-10-14 16:00:01",
                "priceHint": 4,
                "regularMarketPrice": 3.86,
                "regularMarketDayHigh": 3.9,
                "regularMarketDayLow": 3.83,
                "regularMarketVolume": 416686,
                "averageDailyVolume10Day": 672290,
                "averageDailyVolume3Month": 1095100,
                "regularMarketPreviousClose": 3.88,
                "regularMarketSource": "FREE_REALTIME",
                "regularMarketOpen": 3.88,
                "exchange": "NMS",
                "exchangeName": "NasdaqGS",
                "exchangeDataDelayedBy": 0,
                "marketState": "POSTPOST",
                "quoteType": "EQUITY",
                "symbol": "ABUS",
                "underlyingSymbol": null,
                "shortName": "Arbutus Biopharma Corporation",
                "longName": "Arbutus Biopharma Corporation",
                "currency": "USD",
                "quoteSourceName": "Nasdaq Real Time Price",
                "currencySymbol": "$",
                "fromCurrency": null,
                "toCurrency": null,
                "lastMarket": null,
                "marketCap": 730582208
            },
            "financialData": {
                "maxAge": 86400,
                "currentPrice": 3.86,
                "targetHighPrice": 7.0,
                "targetLowPrice": 4.0,
                "targetMeanPrice": 5.0,
                "targetMedianPrice": 5.0,
                "recommendationMean": 2.0,
                "recommendationKey": "buy",
                "numberOfAnalystOpinions": 5,
                "totalCash": 141986000,
                "totalCashPerShare": 0.752,
                "ebitda": -80989000,
                "totalDebt": 7456000,
                "quickRatio": 6.375,
                "currentRatio": 6.56,
                "totalRevenue": 10061000,
                "debtToEquity": 6.089,
                "revenuePerShare": 0.058,
                "returnOnAssets": -0.30586,
                "returnOnEquity": -0.59956,
                "freeCashflow": -42819500,
                "operatingCashflow": -72875000,
                "revenueGrowth": -0.629,
                "grossMargins": 0.0,
                "ebitdaMargins": 0.0,
                "operatingMargins": -12.38239,
                "profitMargins": 0.0,
                "financialCurrency": "USD"
            }
        }
    },
    {
        "AAPL": {
            "defaultKeyStatistics": {
                "maxAge": 1,
                "priceHint": 2,
                "enterpriseValue": 3556219813888,
                "forwardPE": 30.92246,
                "profitMargins": 0.26441,
                "floatShares": 15179506298,
                "sharesOutstanding": 15204100096,
                "sharesShort": 141741381,
                "sharesShortPriorMonth": 135042504,
                "sharesShortPreviousMonthDate": "2024-08-29 20:00:00",
                "dateShortInterest": "2024-09-29 20:00:00",
                "sharesPercentSharesOut": 0.0093,
                "heldPercentInsiders": 0.02704,
                "heldPercentInstitutions": 0.60983,
                "shortRatio": 2.32,
                "shortPercentOfFloat": 0.0093,
                "beta": 1.239,
                "impliedSharesOutstanding": 15303000064,
                "category": null,
                "bookValue": 4.382,
                "priceToBook": 52.78412,
                "fundFamily": null,
                "legalType": null,
                "lastFiscalYearEnd": "2023-09-29 20:00:00",
                "nextFiscalYearEnd": "2024-09-29 20:00:00",
                "mostRecentQuarter": "2024-06-28 20:00:00",
                "earningsQuarterlyGrowth": 0.079,
                "netIncomeToCommon": 101956001792,
                "trailingEps": 6.58,
                "forwardEps": 7.48,
                "pegRatio": 3.07,
                "lastSplitFactor": "4:1",
                "lastSplitDate": "2020-08-30 20:00:00",
                "enterpriseToRevenue": 9.222,
                "enterpriseToEbitda": 26.986,
                "52WeekChange": 0.30567312,
                "SandP52WeekChange": 0.33994555,
                "lastDividendValue": 0.25,
                "lastDividendDate": 1723420800
            },
            "summaryProfile": {
                "address1": "One Apple Park Way",
                "city": "Cupertino",
                "state": "CA",
                "zip": "95014",
                "country": "United States",
                "phone": "408 996 1010",
                "website": "https://www.apple.com",
                "industry": "Consumer Electronics",
                "industryKey": "consumer-electronics",
                "industryDisp": "Consumer Electronics",
                "sector": "Technology",
                "sectorKey": "technology",
                "sectorDisp": "Technology",
                "longBusinessSummary": "Apple Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide. The company offers iPhone, a line of smartphones; Mac, a line of personal computers; iPad, a line of multi-purpose tablets; and wearables, home, and accessories comprising AirPods, Apple TV, Apple Watch, Beats products, and HomePod. It also provides AppleCare support and cloud services; and operates various platforms, including the App Store that allow customers to discover and download applications and digital content, such as books, music, video, games, and podcasts. In addition, the company offers various services, such as Apple Arcade, a game subscription service; Apple Fitness+, a personalized fitness service; Apple Music, which offers users a curated listening experience with on-demand radio stations; Apple News+, a subscription news and magazine service; Apple TV+, which offers exclusive original content; Apple Card, a co-branded credit card; and Apple Pay, a cashless payment service, as well as licenses its intellectual property. The company serves consumers, and small and mid-sized businesses; and the education, enterprise, and government markets. It distributes third-party applications for its products through the App Store. The company also sells its products through its retail and online stores, and direct sales force; and third-party cellular network carriers, wholesalers, retailers, and resellers. Apple Inc. was founded in 1976 and is headquartered in Cupertino, California.",
                "fullTimeEmployees": 161000,
                "companyOfficers": [],
                "irWebsite": "http://investor.apple.com/",
                "maxAge": 86400
            },
            "price": {
                "maxAge": 1,
                "preMarketChangePercent": 0.00514172,
                "preMarketChange": 1.17,
                "preMarketTime": "2024-10-14 09:29:59",
                "preMarketPrice": 228.72,
                "preMarketSource": "FREE_REALTIME",
                "postMarketChangePercent": -0.000108124,
                "postMarketChange": -0.0250092,
                "postMarketTime": "2024-10-14 19:59:59",
                "postMarketPrice": 231.275,
                "postMarketSource": "FREE_REALTIME",
                "regularMarketChangePercent": 0.016479895,
                "regularMarketChange": 3.75,
                "regularMarketTime": "2024-10-14 16:00:01",
                "priceHint": 2,
                "regularMarketPrice": 231.3,
                "regularMarketDayHigh": 231.7278,
                "regularMarketDayLow": 228.6,
                "regularMarketVolume": 32607921,
                "averageDailyVolume10Day": 37219900,
                "averageDailyVolume3Month": 51776510,
                "regularMarketPreviousClose": 227.55,
                "regularMarketSource": "FREE_REALTIME",
                "regularMarketOpen": 228.7,
                "exchange": "NMS",
                "exchangeName": "NasdaqGS",
                "exchangeDataDelayedBy": 0,
                "marketState": "POSTPOST",
                "quoteType": "EQUITY",
                "symbol": "AAPL",
                "underlyingSymbol": null,
                "shortName": "Apple Inc.",
                "longName": "Apple Inc.",
                "currency": "USD",
                "quoteSourceName": "Nasdaq Real Time Price",
                "currencySymbol": "$",
                "fromCurrency": null,
                "toCurrency": null,
                "lastMarket": null,
                "marketCap": 3516708421632
            },
            "financialData": {
                "maxAge": 86400,
                "currentPrice": 231.3,
                "targetHighPrice": 300.0,
                "targetLowPrice": 183.86,
                "targetMeanPrice": 240.78,
                "targetMedianPrice": 243.0,
                "recommendationMean": 2.1,
                "recommendationKey": "buy",
                "numberOfAnalystOpinions": 40,
                "totalCash": 61801000960,
                "totalCashPerShare": 4.065,
                "ebitda": 131781001216,
                "totalDebt": 101304000512,
                "quickRatio": 0.798,
                "currentRatio": 0.953,
                "totalRevenue": 385603010560,
                "debtToEquity": 151.862,
                "revenuePerShare": 24.957,
                "returnOnAssets": 0.22612,
                "returnOnEquity": 1.60583,
                "freeCashflow": 86158123008,
                "operatingCashflow": 113040998400,
                "earningsGrowth": 0.111,
                "revenueGrowth": 0.049,
                "grossMargins": 0.45962003,
                "ebitdaMargins": 0.34175,
                "operatingMargins": 0.29556,
                "profitMargins": 0.26441,
                "financialCurrency": "USD"
            }
        }
    },
    {
        "ACAD": {
            "defaultKeyStatistics": {
                "maxAge": 1,
                "priceHint": 2,
                "enterpriseValue": 2043196032,
                "forwardPE": 18.060242,
                "profitMargins": 0.03432,
                "floatShares": 108459715,
                "sharesOutstanding": 165876000,
                "sharesShort": 7979555,
                "sharesShortPriorMonth": 10266001,
                "sharesShortPreviousMonthDate": "2024-08-29 20:00:00",
                "dateShortInterest": "2024-09-29 20:00:00",
                "sharesPercentSharesOut": 0.0481,
                "heldPercentInsiders": 0.00537,
                "heldPercentInstitutions": 1.00293,
                "shortRatio": 5.86,
                "shortPercentOfFloat": 0.065,
                "beta": 0.383,
                "category": null,
                "bookValue": 3.115,
                "priceToBook": 4.812199,
                "fundFamily": null,
                "legalType": null,
                "lastFiscalYearEnd": "2023-12-30 19:00:00",
                "nextFiscalYearEnd": "2024-12-30 19:00:00",
                "mostRecentQuarter": "2024-06-29 20:00:00",
                "earningsQuarterlyGrowth": 28.972,
                "netIncomeToCommon": 30565000,
                "trailingEps": 0.19,
                "forwardEps": 0.83,
                "pegRatio": -0.08,
                "lastSplitFactor": null,
                "enterpriseToRevenue": 2.294,
                "enterpriseToEbitda": 59.614
            },
            "summaryProfile": {
                "address1": "12830 El Camino Real",
                "address2": "Suite 400",
                "city": "San Diego",
                "state": "CA",
                "zip": "92130",
                "country": "United States",
                "phone": "858 558 2871",
                "fax": "858 212 0513",
                "website": "https://www.acadia.com",
                "industry": "Biotechnology",
                "sector": "Healthcare",
                "longBusinessSummary": "ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.",
                "fullTimeEmployees": 630,
                "companyOfficers": [],
                "maxAge": 86400
            },
            "price": {
                "maxAge": 1,
                "preMarketChangePercent": 0.0,
                "preMarketChange": 0.0,
                "preMarketTime": "2024-10-14 09:18:31",
                "preMarketPrice": 14.92,
                "preMarketSource": "FREE_REALTIME",
                "postMarketChangePercent": -0.00933952,
                "postMarketChange": -0.139999,
                "postMarketTime": "2024-10-14 17:21:40",
                "postMarketPrice": 14.85,
                "postMarketSource": "FREE_REALTIME",
                "regularMarketChangePercent": 0.0046916683,
                "regularMarketChange": 0.069999695,
                "regularMarketTime": "2024-10-14 16:00:01",
                "priceHint": 2,
                "regularMarketPrice": 14.99,
                "regularMarketDayHigh": 15.0104,
                "regularMarketDayLow": 14.78,
                "regularMarketVolume": 782191,
                "averageDailyVolume10Day": 1165440,
                "averageDailyVolume3Month": 1674560,
                "regularMarketPreviousClose": 14.92,
                "regularMarketSource": "FREE_REALTIME",
                "regularMarketOpen": 14.84,
                "exchange": "NMS",
                "exchangeName": "NasdaqGS",
                "exchangeDataDelayedBy": 0,
                "marketState": "POSTPOST",
                "quoteType": "EQUITY",
                "symbol": "ACAD",
                "underlyingSymbol": null,
                "shortName": "ACADIA Pharmaceuticals Inc.",
                "longName": "ACADIA Pharmaceuticals Inc.",
                "currency": "USD",
                "quoteSourceName": "Nasdaq Real Time Price",
                "currencySymbol": "$",
                "fromCurrency": null,
                "lastMarket": null,
                "marketCap": 2486481152
            },
            "financialData": {
                "maxAge": 86400,
                "currentPrice": 14.99,
                "targetHighPrice": 39.0,
                "targetLowPrice": 12.0,
                "targetMeanPrice": 25.28,
                "targetMedianPrice": 26.5,
                "recommendationMean": 2.2,
                "recommendationKey": "buy",
                "numberOfAnalystOpinions": 18,
                "totalCash": 500942016,
                "totalCashPerShare": 3.02,
                "ebitda": 34274000,
                "totalDebt": 57656000,
                "quickRatio": 1.809,
                "currentRatio": 2.158,
                "totalRevenue": 890534016,
                "debtToEquity": 11.159,
                "revenuePerShare": 5.402,
                "returnOnAssets": 0.01832,
                "returnOnEquity": 0.066989996,
                "freeCashflow": 130438376,
                "operatingCashflow": 80526000,
                "earningsGrowth": 28.347,
                "revenueGrowth": 0.464,
                "grossMargins": 0.51343,
                "ebitdaMargins": 0.03849,
                "operatingMargins": 0.12579,
                "profitMargins": 0.03432,
                "financialCurrency": "USD"
            }
        }
    },
    {
        "ABNB": {
            "defaultKeyStatistics": {
                "maxAge": 1,
                "priceHint": 2,
                "enterpriseValue": 76267356160,
                "forwardPE": 29.23861,
                "profitMargins": 0.46111,
                "floatShares": 426006770,
                "sharesOutstanding": 440001984,
                "sharesShort": 13799659,
                "sharesShortPriorMonth": 13237015,
                "sharesShortPreviousMonthDate": "2024-08-29 20:00:00",
                "dateShortInterest": "2024-09-29 20:00:00",
                "sharesPercentSharesOut": 0.0218,
                "heldPercentInsiders": 0.01006,
                "heldPercentInstitutions": 0.77469003,
                "shortRatio": 3.17,
                "shortPercentOfFloat": 0.0317,
                "beta": 1.172,
                "category": null,
                "bookValue": 12.621,
                "priceToBook": 10.679818,
                "fundFamily": null,
                "legalType": null,
                "lastFiscalYearEnd": "2023-12-30 19:00:00",
                "nextFiscalYearEnd": "2024-12-30 19:00:00",
                "mostRecentQuarter": "2024-06-29 20:00:00",
                "earningsQuarterlyGrowth": -0.146,
                "netIncomeToCommon": 4844000256,
                "trailingEps": 7.37,
                "forwardEps": 4.61,
                "pegRatio": 1.76,
                "lastSplitFactor": null,
                "enterpriseToRevenue": 7.26,
                "enterpriseToEbitda": 46.59
            },
            "summaryProfile": {
                "address1": "888 Brannan Street",
                "city": "San Francisco",
                "state": "CA",
                "zip": "94103",
                "country": "United States",
                "phone": "415 510 4027",
                "website": "https://www.airbnb.com",
                "industry": "Travel Services",
                "sector": "Consumer Cyclical",
                "longBusinessSummary": "Airbnb, Inc., together with its subsidiaries, operates a platform that enables hosts to offer stays and experiences to guests worldwide. The company's marketplace connects hosts and guests online or through mobile devices to book spaces and experiences. It primarily offers private rooms, primary homes, and vacation homes. The company was formerly known as AirBed & Breakfast, Inc. and changed its name to Airbnb, Inc. in November 2010. Airbnb, Inc. was founded in 2007 and is headquartered in San Francisco, California.",
                "fullTimeEmployees": 6907,
                "companyOfficers": [],
                "maxAge": 86400
            },
            "price": {
                "maxAge": 1,
                "preMarketChangePercent": -0.0047619,
                "preMarketChange": -0.639999,
                "preMarketTime": "2024-10-14 09:29:59",
                "preMarketPrice": 133.76,
                "preMarketSource": "FREE_REALTIME",
                "postMarketChangePercent": -0.00949624,
                "postMarketChange": -1.28,
                "postMarketTime": "2024-10-14 19:59:31",
                "postMarketPrice": 133.51,
                "postMarketSource": "FREE_REALTIME",
                "regularMarketChangePercent": 0.0029017811,
                "regularMarketChange": 0.3899994,
                "regularMarketTime": "2024-10-14 16:00:01",
                "priceHint": 2,
                "regularMarketPrice": 134.79,
                "regularMarketDayHigh": 134.98,
                "regularMarketDayLow": 133.42,
                "regularMarketVolume": 2209719,
                "averageDailyVolume10Day": 2980790,
                "averageDailyVolume3Month": 4693507,
                "regularMarketPreviousClose": 134.4,
                "regularMarketSource": "FREE_REALTIME",
                "regularMarketOpen": 133.97,
                "exchange": "NMS",
                "exchangeName": "NasdaqGS",
                "exchangeDataDelayedBy": 0,
                "marketState": "POSTPOST",
                "quoteType": "EQUITY",
                "symbol": "ABNB",
                "underlyingSymbol": null,
                "shortName": "Airbnb, Inc.",
                "longName": "Airbnb, Inc.",
                "currency": "USD",
                "quoteSourceName": "Nasdaq Real Time Price",
                "currencySymbol": "$",
                "fromCurrency": null,
                "lastMarket": null,
                "marketCap": 84997758976
            },
            "financialData": {
                "maxAge": 86400,
                "currentPrice": 134.79,
                "targetHighPrice": 195.0,
                "targetLowPrice": 80.0,
                "targetMeanPrice": 127.92,
                "targetMedianPrice": 125.17,
                "recommendationMean": 2.8,
                "recommendationKey": "hold",
                "numberOfAnalystOpinions": 32,
                "totalCash": 11251000320,
                "totalCashPerShare": 17.79,
                "ebitda": 1636999936,
                "totalDebt": 2273999872,
                "quickRatio": 0.722,
                "currentRatio": 1.406,
                "totalRevenue": 10504999936,
                "debtToEquity": 28.418,
                "revenuePerShare": 16.466,
                "returnOnAssets": 0.04205,
                "returnOnEquity": 0.74175,
                "freeCashflow": 3157874944,
                "operatingCashflow": 4361999872,
                "earningsGrowth": -0.125,
                "revenueGrowth": 0.106,
                "grossMargins": 0.82588995,
                "ebitdaMargins": 0.15583,
                "operatingMargins": 0.18086,
                "profitMargins": 0.46111,
                "financialCurrency": "USD"
            }
        }
    },
    {
        "ABOS": {
            "defaultKeyStatistics": {
                "maxAge": 1,
                "priceHint": 4,
                "enterpriseValue": -89560520,
                "forwardPE": -1.5359477,
                "profitMargins": 0.0,
                "floatShares": 32417847,
                "sharesOutstanding": 60079800,
                "sharesShort": 1563575,
                "sharesShortPriorMonth": 1693136,
                "sharesShortPreviousMonthDate": "2024-08-29 20:00:00",
                "dateShortInterest": "2024-09-29 20:00:00",
                "sharesPercentSharesOut": 0.025999999,
                "heldPercentInsiders": 0.11236,
                "heldPercentInstitutions": 0.78422,
                "shortRatio": 8.91,
                "shortPercentOfFloat": 0.0349,
                "beta": 0.072,
                "category": null,
                "bookValue": 4.06,
                "priceToBook": 0.5788177,
                "fundFamily": null,
                "legalType": null,
                "lastFiscalYearEnd": "2023-12-30 19:00:00",
                "nextFiscalYearEnd": "2024-12-30 19:00:00",
                "mostRecentQuarter": "2024-06-29 20:00:00",
                "netIncomeToCommon": -64864000,
                "trailingEps": -1.11,
                "forwardEps": -1.53,
                "pegRatio": -1.06,
                "lastSplitFactor": null,
                "enterpriseToEbitda": 1.169
            },
            "summaryProfile": {
                "address1": "427 Park Street",
                "city": "Charlottesville",
                "state": "VA",
                "zip": "22902",
                "country": "United States",
                "phone": "434 297 1000",
                "website": "https://acumenpharm.com",
                "industry": "Biotechnology",
                "sector": "Healthcare",
                "longBusinessSummary": "Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.",
                "fullTimeEmployees": 51,
                "companyOfficers": [],
                "maxAge": 86400
            },
            "price": {
                "maxAge": 1,
                "preMarketChangePercent": 0.0297873,
                "preMarketChange": 0.0700002,
                "preMarketTime": "2024-10-14 09:27:12",
                "preMarketPrice": 2.42,
                "preMarketSource": "FREE_REALTIME",
                "postMarketChangePercent": 0.017021399,
                "postMarketChange": 0.0400002,
                "postMarketTime": "2024-10-14 16:22:14",
                "postMarketPrice": 2.39,
                "postMarketSource": "FREE_REALTIME",
                "regularMarketChangePercent": 0.0,
                "regularMarketChange": 0.0,
                "regularMarketTime": "2024-10-14 16:00:01",
                "priceHint": 4,
                "regularMarketPrice": 2.35,
                "regularMarketDayHigh": 2.405,
                "regularMarketDayLow": 2.33,
                "regularMarketVolume": 77111,
                "averageDailyVolume10Day": 152170,
                "averageDailyVolume3Month": 222739,
                "regularMarketPreviousClose": 2.35,
                "regularMarketSource": "FREE_REALTIME",
                "regularMarketOpen": 2.37,
                "exchange": "NMS",
                "exchangeName": "NasdaqGS",
                "exchangeDataDelayedBy": 0,
                "marketState": "POSTPOST",
                "quoteType": "EQUITY",
                "symbol": "ABOS",
                "underlyingSymbol": null,
                "shortName": "Acumen Pharmaceuticals, Inc.",
                "longName": "Acumen Pharmaceuticals, Inc.",
                "currency": "USD",
                "quoteSourceName": "Nasdaq Real Time Price",
                "currencySymbol": "$",
                "fromCurrency": null,
                "lastMarket": null,
                "marketCap": 141187520
            },
            "financialData": {
                "maxAge": 86400,
                "currentPrice": 2.35,
                "targetHighPrice": 15.0,
                "targetLowPrice": 6.0,
                "targetMeanPrice": 11.2,
                "targetMedianPrice": 11.0,
                "recommendationMean": 1.5,
                "recommendationKey": "strong_buy",
                "numberOfAnalystOpinions": 5,
                "totalCash": 260472000,
                "totalCashPerShare": 4.335,
                "ebitda": -76615000,
                "totalDebt": 29724000,
                "quickRatio": 16.957,
                "currentRatio": 17.369,
                "debtToEquity": 12.185,
                "returnOnAssets": -0.20555,
                "returnOnEquity": -0.31425,
                "freeCashflow": -36267624,
                "operatingCashflow": -55623000,
                "grossMargins": 0.0,
                "ebitdaMargins": 0.0,
                "operatingMargins": 0.0,
                "profitMargins": 0.0,
                "financialCurrency": "USD"
            }
        }
    },
    {
        "ACCD": {
            "defaultKeyStatistics": {
                "maxAge": 1,
                "priceHint": 4,
                "enterpriseValue": 300029088,
                "forwardPE": -4.2674417,
                "profitMargins": -0.18160999,
                "floatShares": 68581350,
                "sharesOutstanding": 80537104,
                "sharesShort": 4859444,
                "sharesShortPriorMonth": 4239349,
                "sharesShortPreviousMonthDate": "2024-08-29 20:00:00",
                "dateShortInterest": "2024-09-29 20:00:00",
                "sharesPercentSharesOut": 0.060300004,
                "heldPercentInsiders": 0.030620001,
                "heldPercentInstitutions": 0.81806,
                "shortRatio": 5.48,
                "shortPercentOfFloat": 0.0621,
                "beta": 1.993,
                "category": null,
                "bookValue": 5.264,
                "priceToBook": 0.6971885,
                "fundFamily": null,
                "legalType": null,
                "lastFiscalYearEnd": "2024-02-28 19:00:00",
                "nextFiscalYearEnd": "2025-02-27 19:00:00",
                "mostRecentQuarter": "2024-08-30 20:00:00",
                "netIncomeToCommon": -80097000,
                "trailingEps": -1.02,
                "forwardEps": -0.86,
                "pegRatio": 4.39,
                "lastSplitFactor": null,
                "enterpriseToRevenue": 0.68,
                "enterpriseToEbitda": -5.596
            },
            "summaryProfile": {
                "address1": "1201 Third Avenue",
                "address2": "Suite 1700",
                "city": "Seattle",
                "state": "WA",
                "zip": "98101",
                "country": "United States",
                "phone": "206 926 8100",
                "website": "https://www.accolade.com",
                "industry": "Health Information Services",
                "sector": "Healthcare",
                "longBusinessSummary": "Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians. It also provides medical opinion services to commercial customers; and navigation, care, and advocacy solutions. In addition, the company offers medical consultations that connect patients to qualified condition-specific specialists for adult and pediatric care; and primary care and mental health support solutions. It serves employers who provide employees and their families a single place to turn for their health, healthcare, and benefits needs. The company was incorporated in 2007 and is headquartered in Seattle, Washington.",
                "fullTimeEmployees": 2400,
                "companyOfficers": [],
                "maxAge": 86400
            },
            "price": {
                "maxAge": 1,
                "preMarketChangePercent": 0.0,
                "preMarketChange": 0.0,
                "preMarketTime": "2024-10-14 09:29:30",
                "preMarketPrice": 3.79,
                "preMarketSource": "FREE_REALTIME",
                "postMarketChangePercent": -0.0054495903,
                "postMarketChange": -0.02,
                "postMarketTime": "2024-10-14 19:02:43",
                "postMarketPrice": 3.65,
                "postMarketSource": "FREE_REALTIME",
                "regularMarketChangePercent": -0.03166224,
                "regularMarketChange": -0.119999886,
                "regularMarketTime": "2024-10-14 16:00:01",
                "priceHint": 4,
                "regularMarketPrice": 3.67,
                "regularMarketDayHigh": 3.78,
                "regularMarketDayLow": 3.62,
                "regularMarketVolume": 1430992,
                "averageDailyVolume10Day": 2213890,
                "averageDailyVolume3Month": 1231157,
                "regularMarketPreviousClose": 3.79,
                "regularMarketSource": "FREE_REALTIME",
                "regularMarketOpen": 3.78,
                "exchange": "NMS",
                "exchangeName": "NasdaqGS",
                "exchangeDataDelayedBy": 0,
                "marketState": "POSTPOST",
                "quoteType": "EQUITY",
                "symbol": "ACCD",
                "underlyingSymbol": null,
                "shortName": "Accolade, Inc.",
                "longName": "Accolade, Inc.",
                "currency": "USD",
                "quoteSourceName": "Nasdaq Real Time Price",
                "currencySymbol": "$",
                "fromCurrency": null,
                "lastMarket": null,
                "marketCap": 305235360
            },
            "financialData": {
                "maxAge": 86400,
                "currentPrice": 3.67,
                "targetHighPrice": 9.5,
                "targetLowPrice": 5.0,
                "targetMeanPrice": 7.08,
                "targetMedianPrice": 7.0,
                "recommendationMean": 1.9,
                "recommendationKey": "buy",
                "numberOfAnalystOpinions": 13,
                "totalCash": 234350000,
                "totalCashPerShare": 2.91,
                "ebitda": -53619000,
                "totalDebt": 238808000,
                "quickRatio": 2.569,
                "currentRatio": 2.72,
                "totalRevenue": 441028000,
                "debtToEquity": 56.446,
                "revenuePerShare": 5.706,
                "returnOnAssets": -0.07271,
                "returnOnEquity": -0.18611999,
                "freeCashflow": 33368876,
                "operatingCashflow": 8180000,
                "revenueGrowth": 0.098,
                "grossMargins": 0.48238,
                "ebitdaMargins": -0.12158,
                "operatingMargins": -0.2364,
                "profitMargins": -0.18160999,
                "financialCurrency": "USD"
            }
        }
    },
    {
        "ABCL": {
            "defaultKeyStatistics": {
                "maxAge": 1,
                "priceHint": 4,
                "enterpriseValue": 144255136,
                "forwardPE": -3.652174,
                "profitMargins": 0.0,
                "floatShares": 188553527,
                "sharesOutstanding": 294665984,
                "sharesShort": 17061423,
                "sharesShortPriorMonth": 17551585,
                "sharesShortPreviousMonthDate": "2024-08-29 20:00:00",
                "dateShortInterest": "2024-09-29 20:00:00",
                "sharesPercentSharesOut": 0.0579,
                "heldPercentInsiders": 0.28053,
                "heldPercentInstitutions": 0.38327998,
                "shortRatio": 7.58,
                "shortPercentOfFloat": 0.0752,
                "beta": 0.372,
                "impliedSharesOutstanding": 304056992,
                "category": null,
                "bookValue": 3.77,
                "priceToBook": 0.66843504,
                "fundFamily": null,
                "legalType": null,
                "lastFiscalYearEnd": "2023-12-30 19:00:00",
                "nextFiscalYearEnd": "2024-12-30 19:00:00",
                "mostRecentQuarter": "2024-06-29 20:00:00",
                "netIncomeToCommon": -153300000,
                "trailingEps": -0.51,
                "forwardEps": -0.69,
                "pegRatio": -0.43,
                "lastSplitFactor": null,
                "enterpriseToRevenue": 4.364,
                "enterpriseToEbitda": -0.672,
                "52WeekChange": -0.42727274,
                "SandP52WeekChange": 0.33994555
            },
            "summaryProfile": {
                "address1": "2215 Yukon Street",
                "city": "Vancouver",
                "state": "BC",
                "zip": "V5Y 0A1",
                "country": "Canada",
                "phone": "604 559 9005",
                "website": "https://www.abcellera.com",
                "industry": "Biotechnology",
                "industryKey": "biotechnology",
                "industryDisp": "Biotechnology",
                "sector": "Healthcare",
                "sectorKey": "healthcare",
                "sectorDisp": "Healthcare",
                "longBusinessSummary": "AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.",
                "fullTimeEmployees": 586,
                "companyOfficers": [],
                "maxAge": 86400
            },
            "price": {
                "maxAge": 1,
                "preMarketChangePercent": 0.011583,
                "preMarketChange": 0.03,
                "preMarketTime": "2024-10-14 09:20:59",
                "preMarketPrice": 2.62,
                "preMarketSource": "FREE_REALTIME",
                "postMarketChangePercent": 0.0119048,
                "postMarketChange": 0.03,
                "postMarketTime": "2024-10-14 19:48:42",
                "postMarketPrice": 2.55,
                "postMarketSource": "FREE_REALTIME",
                "regularMarketChangePercent": -0.027027002,
                "regularMarketChange": -0.06999993,
                "regularMarketTime": "2024-10-14 16:00:01",
                "priceHint": 4,
                "regularMarketPrice": 2.52,
                "regularMarketDayHigh": 2.59,
                "regularMarketDayLow": 2.43,
                "regularMarketVolume": 2004064,
                "averageDailyVolume10Day": 1574880,
                "averageDailyVolume3Month": 1753985,
                "regularMarketPreviousClose": 2.59,
                "regularMarketSource": "FREE_REALTIME",
                "regularMarketOpen": 2.59,
                "exchange": "NMS",
                "exchangeName": "NasdaqGS",
                "exchangeDataDelayedBy": 0,
                "marketState": "POSTPOST",
                "quoteType": "EQUITY",
                "symbol": "ABCL",
                "underlyingSymbol": null,
                "shortName": "AbCellera Biologics Inc.",
                "longName": "AbCellera Biologics Inc.",
                "currency": "USD",
                "quoteSourceName": "Nasdaq Real Time Price",
                "currencySymbol": "$",
                "fromCurrency": null,
                "toCurrency": null,
                "lastMarket": null,
                "marketCap": 766223616
            },
            "financialData": {
                "maxAge": 86400,
                "currentPrice": 2.52,
                "targetHighPrice": 28.0,
                "targetLowPrice": 5.0,
                "targetMeanPrice": 15.43,
                "targetMedianPrice": 14.0,
                "recommendationMean": 1.9,
                "recommendationKey": "buy",
                "numberOfAnalystOpinions": 7,
                "totalCash": 670355968,
                "totalCashPerShare": 2.275,
                "ebitda": -214655008,
                "totalDebt": 72054000,
                "quickRatio": 10.487,
                "currentRatio": 10.963,
                "totalRevenue": 33054000,
                "debtToEquity": 6.486,
                "revenuePerShare": 0.113,
                "returnOnAssets": -0.11412,
                "returnOnEquity": -0.13297,
                "freeCashflow": -133388496,
                "operatingCashflow": -91391000,
                "revenueGrowth": -0.272,
                "grossMargins": 0.0,
                "ebitdaMargins": 0.0,
                "operatingMargins": -12.76171,
                "profitMargins": 0.0,
                "financialCurrency": "USD"
            }
        }
    }
]